AACE/ACE Position statement on the use of follow-on biologics and biosimilars for endocrine diseases

Vivian A. Fonseca, Zachary T. Bloomgarden, Samuel Dagogo-Jack, George Grunberger, Daniel Einhorn, Alan J. Garber, Yehuda Handelsman, Irl B. Hirsch, Guillermo E. Umpierrez

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

This document represents the official position of the American Association of Clinical Endocrinologists and American College of Endocrinology. Where there were no randomized controlled trials or specific U.S. FDA labeling for issues in clinical practice, the participating clinical experts utilized their judgment and experience. Every effort was made to achieve consensus among the committee members. Position and consensus statements are meant to provide guidance, but they are not to be considered prescriptive for any individual patient and cannot replace the judgment of a clinician.

Original languageEnglish (US)
Pages (from-to)1345-1349
Number of pages5
JournalEndocrine Practice
Volume23
Issue number11
DOIs
StatePublished - Nov 1 2017

Fingerprint

Biosimilar Pharmaceuticals
Endocrine System Diseases
Biological Products
Consensus
Committee Membership
Endocrinology
Randomized Controlled Trials

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Fonseca, V. A., Bloomgarden, Z. T., Dagogo-Jack, S., Grunberger, G., Einhorn, D., Garber, A. J., ... Umpierrez, G. E. (2017). AACE/ACE Position statement on the use of follow-on biologics and biosimilars for endocrine diseases. Endocrine Practice, 23(11), 1345-1349. https://doi.org/10.4158/EP-2017-0052

AACE/ACE Position statement on the use of follow-on biologics and biosimilars for endocrine diseases. / Fonseca, Vivian A.; Bloomgarden, Zachary T.; Dagogo-Jack, Samuel; Grunberger, George; Einhorn, Daniel; Garber, Alan J.; Handelsman, Yehuda; Hirsch, Irl B.; Umpierrez, Guillermo E.

In: Endocrine Practice, Vol. 23, No. 11, 01.11.2017, p. 1345-1349.

Research output: Contribution to journalArticle

Fonseca, VA, Bloomgarden, ZT, Dagogo-Jack, S, Grunberger, G, Einhorn, D, Garber, AJ, Handelsman, Y, Hirsch, IB & Umpierrez, GE 2017, 'AACE/ACE Position statement on the use of follow-on biologics and biosimilars for endocrine diseases', Endocrine Practice, vol. 23, no. 11, pp. 1345-1349. https://doi.org/10.4158/EP-2017-0052
Fonseca, Vivian A. ; Bloomgarden, Zachary T. ; Dagogo-Jack, Samuel ; Grunberger, George ; Einhorn, Daniel ; Garber, Alan J. ; Handelsman, Yehuda ; Hirsch, Irl B. ; Umpierrez, Guillermo E. / AACE/ACE Position statement on the use of follow-on biologics and biosimilars for endocrine diseases. In: Endocrine Practice. 2017 ; Vol. 23, No. 11. pp. 1345-1349.
@article{a065833bcc3a442cb62b8200258bb5e9,
title = "AACE/ACE Position statement on the use of follow-on biologics and biosimilars for endocrine diseases",
abstract = "This document represents the official position of the American Association of Clinical Endocrinologists and American College of Endocrinology. Where there were no randomized controlled trials or specific U.S. FDA labeling for issues in clinical practice, the participating clinical experts utilized their judgment and experience. Every effort was made to achieve consensus among the committee members. Position and consensus statements are meant to provide guidance, but they are not to be considered prescriptive for any individual patient and cannot replace the judgment of a clinician.",
author = "Fonseca, {Vivian A.} and Bloomgarden, {Zachary T.} and Samuel Dagogo-Jack and George Grunberger and Daniel Einhorn and Garber, {Alan J.} and Yehuda Handelsman and Hirsch, {Irl B.} and Umpierrez, {Guillermo E.}",
year = "2017",
month = "11",
day = "1",
doi = "10.4158/EP-2017-0052",
language = "English (US)",
volume = "23",
pages = "1345--1349",
journal = "Endocrine Practice",
issn = "1530-891X",
publisher = "American Association of Clinical Endocrinology",
number = "11",

}

TY - JOUR

T1 - AACE/ACE Position statement on the use of follow-on biologics and biosimilars for endocrine diseases

AU - Fonseca, Vivian A.

AU - Bloomgarden, Zachary T.

AU - Dagogo-Jack, Samuel

AU - Grunberger, George

AU - Einhorn, Daniel

AU - Garber, Alan J.

AU - Handelsman, Yehuda

AU - Hirsch, Irl B.

AU - Umpierrez, Guillermo E.

PY - 2017/11/1

Y1 - 2017/11/1

N2 - This document represents the official position of the American Association of Clinical Endocrinologists and American College of Endocrinology. Where there were no randomized controlled trials or specific U.S. FDA labeling for issues in clinical practice, the participating clinical experts utilized their judgment and experience. Every effort was made to achieve consensus among the committee members. Position and consensus statements are meant to provide guidance, but they are not to be considered prescriptive for any individual patient and cannot replace the judgment of a clinician.

AB - This document represents the official position of the American Association of Clinical Endocrinologists and American College of Endocrinology. Where there were no randomized controlled trials or specific U.S. FDA labeling for issues in clinical practice, the participating clinical experts utilized their judgment and experience. Every effort was made to achieve consensus among the committee members. Position and consensus statements are meant to provide guidance, but they are not to be considered prescriptive for any individual patient and cannot replace the judgment of a clinician.

UR - http://www.scopus.com/inward/record.url?scp=85042622615&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042622615&partnerID=8YFLogxK

U2 - 10.4158/EP-2017-0052

DO - 10.4158/EP-2017-0052

M3 - Article

VL - 23

SP - 1345

EP - 1349

JO - Endocrine Practice

JF - Endocrine Practice

SN - 1530-891X

IS - 11

ER -